Status:

COMPLETED

Prospective Study for Safety and Efficacy of InSpace™ in Rotator Cuff Tear Subjects

Lead Sponsor:

OrthoSpace Ltd.

Conditions:

Rotator Cuff Tear

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Title: One-arm, international, multi-center with competitive recruitment, prospective study to assess the safety and efficacy of OrthoSpace's InSpace™ in rotator cuff tear subjects scheduled for surge...

Detailed Description

The OrthoSpace's InSpace™ biodegradable sub-acromial spacer (balloon) will be inserted at the end of the routine arthroscopy between the humerus head and the acromion.

Eligibility Criteria

Inclusion

  • Age 18 or older.
  • Diagnosed with Rotator Cuff tear and are scheduled for surgery.
  • X-Ray of treated shoulder with no unrelated pathology and imaging (ultrasound or MRI) showing Rotator Cuff tear.
  • Persistent pain and functional disability for at least 4 months.
  • Documented failure of conservative treatment.
  • Blood work up to two weeks before implantation as follow:
  • Normal CBC
  • Normal electrolytes (potassium, chloride, phosphorous, sodium)
  • Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3
  • Platelets ≥ 100,000 cells/mm3
  • Hemoglobin ≥ 10.0 g/dl
  • Adequate renal function, with serum creatinine ≤ 2.0 mg/dl
  • Adequate liver function, with serum bilirubin \< 2.0 mg/dl
  • Adequate liver function with SGOT/SGPT \< 2.5 x the upper normal limit
  • Normal values of the PT, PTT and INR tests
  • Negative for HIV and Hepatitis B or C
  • Mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and requirements
  • For Woman of Child Bearing Potential (WOCBP), negative pregnancy test and willingness to use birth control during the study.
  • Singed Informed Consent Form.

Exclusion

  • Evidence of significant osteoarthritis or cartilage damage in the shoulder.
  • Evidence of glenohumeral instability.
  • Previous surgeries of the shoulder .
  • Evidence of major joint trauma, infection, or necrosis in the shoulder.
  • Patients unable to provide informed consent due to language barrier or mental status.
  • Patients with a major medical condition that would affect quality of life and influence the results of the study (Including, but not limited to HIV, hepatitis, active malignancy in the past 5 years, transmural MI, CVA and other impaired neurological status, CHF or unstable angina in the past 6 months).
  • Patients unwilling to be followed for the duration of the study.
  • Acute infection requiring intravenous antibiotics at the time of screening.
  • Other shoulder pain of unknown etiology.
  • Paget's disease, osteomalacia or any other metabolic bone disease.
  • Severe diabetes mellitus requiring daily insulin management.
  • Bleeding disorders.
  • Known cognitive disorder.
  • Concurrent participation in any other clinical study.
  • Physician objection.
  • Subjects with sign of cervical root irritation.
  • Chronic lung disease
  • Trauma subjects
  • For WOCBP, a positive pregnancy test.

Key Trial Info

Start Date :

July 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2014

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT00916994

Start Date

July 1 2009

End Date

June 1 2014

Last Update

March 11 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wolfson Medical Center

Holon, Israel, 58100